Exactly! "or risk leronlimab being controlled from elsewhere with serious vicious consequences to their revenue streams". A BO or partnership from a company headquartered in a country that doesn't give a rats a## about the FDA not only would bring a serious bump in sp, but the future would be bright as well. I think this would be the best solution for all involved, as patients would be able to receive the therapeutics that they need, and other countries would not hesitate to order leronlimab for fear of the FDA imo.
News 
Market Data 
Discover 
AI
